Results 1 to 10 of about 46,383 (210)

The Impact of the Core-Shell Fiber Composition on the Properties and Stability of the Electrospun Films [PDF]

Nanotechnology, Science and Applications
Ewelina Łyszczarz,1 Aleksandra Rezka,1 Dorota Majda,2 Witold Jamróz,1 Aleksander Mendyk1 1Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Lesser Poland Voivodeship,
Łyszczarz E, Rezka A, Majda D, Jamróz W, Mendyk A   +4 more
doaj   +2 more sources

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. [PDF]

PLoS ONE, 2014
BackgroundRifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of drug-drug interactions. Rifabutin has been proposed as an alternative rifamycin, but there is concern that the current
Nguyen Thi Ngoc Lan, Nguyen Thi Nguyet Thu, Aurélie Barrail-Tran, Nguyen Hong Duc, Nguyen Ngoc Lan, Didier Laureillard, Truong Thi Xuan Lien, Laurence Borand, Catherine Quillet, Catherine Connolly, Dominique Lagarde, Alexander Pym, Christian Lienhardt, Nguyen Huy Dung, Anne-Marie Taburet, Anthony D Harries   +15 more
doaj   +6 more sources

A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease [PDF]

, 2016
BACKGROUND: Cervical cancer is the most common female malignancy in the developing nations and the third most common cancer in women globally. An effective, inexpensive and self-applied topical treatment would be an ideal solution for treatment of ...
A Kwara, Alex M. Mwaniki, Anthony W. Oliver, BG Lindeque, C Van Pachterbeke, CD Lahiri, CT Lin, DM Parkin, FP Chen, FX Bosch, G Barillari, G Batman, G Batman, Gavin Batman, H zur Hausen, HC Kitchener, Helen Stringfellow, HU Bernard, Ian N. Hampson, Innocent O. Maranga, IO Maranga, JA Passmore, JM Walboomers, L Hampson, L Rahangdale, Lynne Hampson, M Temmerman, Millicent S. Masinde, Minaxi Desai, MV Pasley, NF Schlecht, Parmenas M. Okemwa, Peter Gichangi, Pierre Martin-Hirsch, PL Martin-Hirsch, PL Stern, R Sankaranarayanan, R Sankaranarayanan, R Sankaranarayanan, RD Alvarez, SP Day, TC Wright Jr., Vikrant Sahasrabuddhe, W Prendiville, WA Chow, WB Bernstein, XH Tao, Xiaotong He, Z Djerada   +48 more
core   +24 more sources

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019 [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19).
Ji-Won Kim, Eun Jin Kim, Hyun Hee Kwon, Chi Young Jung, Kyung Chan Kim, Jung-Yoon Choe, Hyo-Lim Hong   +6 more
doaj   +1 more source

Lopinavir

Reactions Weekly, 2006
europepmc   +2 more sources

COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?

Pharmaceuticals, 2021
The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the ...
Jean Jacques Vanden Eynde
doaj   +1 more source

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Frontiers in Pharmacology, 2021
Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods:
Mario Karolyi, Sara Omid, Erich Pawelka, Bernd Jilma, Thomas Stimpfl, Christian Schoergenhofer, Hermann Laferl, Tamara Seitz, Marianna Traugott, Christoph Wenisch, Alexander Zoufaly   +10 more
doaj   +1 more source

Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report

Frontiers in Pharmacology, 2023
With the improving life expectancy of patients with human immunodeficiency virus (HIV), there is an increasing health concern of potential toxicity and drug interactions of long-term antiretroviral therapies.
Xuechun Mu, Yujiao Duan, Qiuhua Xu, Sa Wang, Guiju Gao, Ning Han, Hongxin Zhao   +6 more
doaj   +1 more source

Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether‐à‐go‐go–Related Gene and Cav1.2

Frontiers in Pharmacology, 2022
Background: Old drugs for new indications in the novel coronavirus disease of 2019 (COVID-19) pandemic have raised concerns regarding cardiotoxicity, especially the development of drug-induced QT prolongation.
Zequn Zheng, Zequn Zheng, Zequn Zheng, Dihui Cai, Dihui Cai, Yin Fu, Yin Fu, Ying Wang, Yongfei Song, Yongfei Song, Jiangfang Lian, Jiangfang Lian   +11 more
doaj   +1 more source

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Терапевтический архив, 2021
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of ...
Natalia Yu. Pshenichnaya, Elena N. Kareva, Irina A. Leneva, Vilya A. Bulgakova, Irina E. Kravchenko, Irina V. Nikolaeva, Antonina I. Grekova, Antonina P. Ivanova, Larisa V. Puzyreva, Guzel M. Khasanova, Svetlana N. Orlova, Elena P. Tikhonova, Vladimir A. Petrov, Oleg V. Malinin, Natalia V. Kolaeva, Elena V. Volchkova, Nina N. Kanshina, Vladimir P. Chulanov   +17 more
doaj   +1 more source